AP2001002181A0 - Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses. - Google Patents
Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses.Info
- Publication number
- AP2001002181A0 AP2001002181A0 APAP/P/2001/002181A AP2001002181A AP2001002181A0 AP 2001002181 A0 AP2001002181 A0 AP 2001002181A0 AP 2001002181 A AP2001002181 A AP 2001002181A AP 2001002181 A0 AP2001002181 A0 AP 2001002181A0
- Authority
- AP
- ARIPO
- Prior art keywords
- virus
- compounds
- hepatitis
- treatment
- metabolites
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 241000700605 Viruses Species 0.000 title abstract 5
- 241000711549 Hepacivirus C Species 0.000 title abstract 2
- 239000002207 metabolite Substances 0.000 title abstract 2
- 239000002243 precursor Substances 0.000 title abstract 2
- 208000000255 Togaviridae Infections Diseases 0.000 abstract 2
- 241000710929 Alphavirus Species 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 241000710831 Flavivirus Species 0.000 abstract 1
- 241000531123 GB virus C Species 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 206010019773 Hepatitis G Diseases 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 241000710778 Pestivirus Species 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 241000710799 Rubella virus Species 0.000 abstract 1
- 241000710772 Yellow fever virus Species 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000009423 ventilation Methods 0.000 abstract 1
- 229940051021 yellow-fever virus Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
The invention provides the use of 17-ketosteroid compounds, as well as derivatives, metabolites and precursors of such compounds, and pharmaceutically acceptable salts of any of these compounds, collectively defined herein as the "compounds of the present invention", in the treatment of prevention of hepatitis C type virus and/or hepatitis G type virus in patients in need of such treatment. in addition, the invention provides methods to treat or prevent togavirus infections, including infections by one or more alphaviruses, flaviviruses, such as yellow fever virus, hepatitis C virus and hepatitis G virus, rubella viruses, or pestiviruses, such as bovine virus diarrhea virus. In addition, the invention provides combination therapies including administration of one or more compound selected from plasma concentration-enhancing compounds, macrophage stimulating factor, oxidation agents, ribavirin and alpha interferon, and/or oxygen ventilation. The compounds of the present invention may also be used to ameliorate or reduce one or more symptoms associated with a togavirus infection.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10992498P | 1998-11-24 | 1998-11-24 | |
| US12408799P | 1999-03-11 | 1999-03-11 | |
| US12605699P | 1999-03-23 | 1999-03-23 | |
| PCT/US1999/028082 WO2000032177A2 (en) | 1998-11-24 | 1999-11-24 | Use of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2001002181A0 true AP2001002181A0 (en) | 2001-05-24 |
Family
ID=27380740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2001/002181A AP2001002181A0 (en) | 1998-11-24 | 1999-11-24 | Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1133287A2 (en) |
| JP (1) | JP2002531397A (en) |
| KR (1) | KR20010101074A (en) |
| CN (1) | CN1328463A (en) |
| AP (1) | AP2001002181A0 (en) |
| AU (1) | AU775614B2 (en) |
| BR (1) | BR9915644A (en) |
| CA (1) | CA2352205A1 (en) |
| HK (1) | HK1042426A1 (en) |
| ID (1) | ID29864A (en) |
| IL (2) | IL142942A0 (en) |
| NZ (1) | NZ511721A (en) |
| OA (1) | OA11716A (en) |
| WO (1) | WO2000032177A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667299B1 (en) | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| EP1223928A2 (en) | 1999-07-08 | 2002-07-24 | Patrick Thomas Prendergast | Use of flavones, coumarins and related compounds to treat infections |
| PT1955700E (en) | 1999-09-30 | 2011-05-04 | Harbor Biosciences Inc | Therapeutic treatment of androgen receptor driven conditions |
| JP2005535664A (en) * | 2002-07-02 | 2005-11-24 | コーセプト セラピューティクス， インコーポレイテッド | Methods for treating psychosis associated with interferon-alpha therapy |
| EP2298315A1 (en) * | 2002-08-28 | 2011-03-23 | Harbor BioSciences, Inc. | Therapeutic treatment methods |
| PT2219642E (en) * | 2007-11-15 | 2011-10-18 | Madaus Gmbh | Silibinin component for the treatment of hepatitis |
| CN102993148B (en) * | 2011-09-13 | 2015-12-09 | 复旦大学 | Quercetin derivative or its analogue and application thereof |
| WO2013178782A1 (en) * | 2012-05-30 | 2013-12-05 | Universidad De Zaragoza | Allosteric inhibitors of ns3 protease from hepatitis c virus |
| CN108003212A (en) * | 2017-12-24 | 2018-05-08 | 扬州工业职业技术学院 | A kind of dehydroepiandros-sterone -6- glucoside derivatives and its application as anti hepatitis C virus drug |
| CN110452280B (en) * | 2019-07-25 | 2020-11-17 | 中国人民解放军第二军医大学 | Tetracyclic triterpenic acid derivative and preparation method and application thereof |
| CA3193390A1 (en) * | 2020-09-22 | 2022-03-31 | Andrey Factor | Nebulizer and nebulized anti-virals |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL194728C (en) * | 1987-04-16 | 2003-01-07 | Hollis Eden Pharmaceuticals | Pharmaceutical preparation suitable for the prophylaxis or therapy of a retroviral infection or a complication or consequence thereof. |
| US5837269A (en) * | 1989-09-25 | 1998-11-17 | University Of Utah Research Foundation | Vaccine compositions and method for enhancing an immune response |
| KR20000005539A (en) * | 1996-04-17 | 2000-01-25 | 패트릭 티. 프렌더가스트 | Dhea combination therapy |
| AU5221998A (en) * | 1997-04-17 | 1998-11-13 | Patrick T. Prendergast | Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors |
-
1999
- 1999-11-24 OA OA1200100128A patent/OA11716A/en unknown
- 1999-11-24 JP JP2000584873A patent/JP2002531397A/en active Pending
- 1999-11-24 CN CN99813658A patent/CN1328463A/en active Pending
- 1999-11-24 NZ NZ511721A patent/NZ511721A/en unknown
- 1999-11-24 AU AU31052/00A patent/AU775614B2/en not_active Ceased
- 1999-11-24 CA CA002352205A patent/CA2352205A1/en not_active Abandoned
- 1999-11-24 KR KR1020017006525A patent/KR20010101074A/en not_active Ceased
- 1999-11-24 BR BR9915644-0A patent/BR9915644A/en not_active Application Discontinuation
- 1999-11-24 WO PCT/US1999/028082 patent/WO2000032177A2/en not_active Ceased
- 1999-11-24 HK HK02102267.0A patent/HK1042426A1/en unknown
- 1999-11-24 IL IL14294299A patent/IL142942A0/en active IP Right Grant
- 1999-11-24 ID IDW00200101129A patent/ID29864A/en unknown
- 1999-11-24 AP APAP/P/2001/002181A patent/AP2001002181A0/en unknown
- 1999-11-24 EP EP99965050A patent/EP1133287A2/en not_active Withdrawn
-
2001
- 2001-05-03 IL IL142942A patent/IL142942A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU775614B2 (en) | 2004-08-05 |
| CA2352205A1 (en) | 2000-06-08 |
| EP1133287A2 (en) | 2001-09-19 |
| HK1042426A1 (en) | 2002-08-16 |
| WO2000032177A3 (en) | 2001-03-22 |
| BR9915644A (en) | 2001-08-07 |
| CN1328463A (en) | 2001-12-26 |
| IL142942A (en) | 2006-08-20 |
| NZ511721A (en) | 2004-07-30 |
| ID29864A (en) | 2001-10-18 |
| KR20010101074A (en) | 2001-11-14 |
| IL142942A0 (en) | 2002-04-21 |
| WO2000032177A2 (en) | 2000-06-08 |
| JP2002531397A (en) | 2002-09-24 |
| AU3105200A (en) | 2000-06-19 |
| OA11716A (en) | 2005-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP1771A (en) | 3'-Prodrugs of 2'-deoxy-?-L-nucleosides. | |
| MXPA04012779A (en) | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections. | |
| TW200500374A (en) | 2' and 3' -nucleoside produrgs for treating flavivridae infections | |
| AU2002360592A8 (en) | Inhibitors of hepatitis c virus | |
| PT1387681E (en) | Use of castanospermine derivatives for the treatment of hepatitis c | |
| AP1727A (en) | Methods and compositions for treating flaviviruses and pestiviruses. | |
| TWI317735B (en) | Methods and compositions for treating hepatitis c virus | |
| UA66744C2 (en) | 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections | |
| MXPA03008623A (en) | Pharmaceutical combinations for the treatment of cancer. | |
| ID27290A (en) | USE OF 1,5-DIDEOKSI-1,5-IMINO-D-GLUSITOL-N-SUBSTITUTED N-COMPOUND IN TREATMENT OF HEPATITIC VIRUS INFECTION | |
| AP2001002181A0 (en) | Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses. | |
| AP9801286A0 (en) | Therapeutic compounds. | |
| TW200501940A (en) | Virus therapeutic drug | |
| MD940152A (en) | Pharmaceutical composition for the treatment of infections and diseases caused by Hepatitis B Virus (HBV) | |
| SG165996A1 (en) | Combination therapies with l-fmau for the treatment of hepatitis b virus infection | |
| ATE348628T1 (en) | TREATING HEPATITIS C WITH THYMOSIN, INTERFERON AND RIBAVIRIN | |
| AP2001002167A0 (en) | Use of 17-ketosteroids for the treatment of toxoplasmosis and crytosporidiosis | |
| UA31078A (en) | HUMAN IMMUNODEFICIENCY VIRUS INHIBITOR (DARIMID) | |
| SG153666A1 (en) | Treatment of hepatitis b virus infection with human monoclonal antibodies |